NATR Company Profile

An eye-catching deterioration in Sales at the company over the fourth quarter of 2022

For the fourth quarter of 2022 earnings season company decreased a loss per share of $-0.03 per share compare to $-0.22 a year before and EPS improved from $-0.07 per share from the prior quarter.

Sales faded by -49.855 % to $1.45 millions from $2.88 millions in the similar quarter a year before and sequentially Sales Tumbled by -41.135 % from $2.46 millions.

For the October to December 31 2022 span Solid Biosciences Inc decreased a loss per share of $-0.13 per share compare to $-0.16 a year prior and EPS improved from $-2.71 per share from the previous reporting season.

Sales remained unscathed to $0.00 millions from $3.15 millions in the comparable reporting season a year prior and sequentially Sales Tumbled from $0.00 millions.

Sales fall back widely at Wave Life Sciences Ltd over the financial span ending December 31 2022

For the financial fourth quarter of 2022 Wave Life Sciences Ltd decreased a loss per share of $-0.32 per share compare to $-0.60 a year before and Income per Share improved from $-0.42 per share from the previous financial reporting period.

Sales crumbled by -29.802 % to $1.24 millions from $1.77 millions in the corresponding financial reporting period a year before and sequentially Sales doubled by 334.737 % from $0.29 millions.

Magenta Therapeutics Inc reported operating shortfall in the fourth quarter of 2022

The Major Pharmaceutical Preparations sector advisors begin to scrutinize the fourth quarter of 2022 performance. Now they observe operating shortfall of $-21.732 millions, from the Magenta Therapeutics Inc, which hasn't mentioned any top-line still, for the respective October to December 31 2022 financial reporting period.

In the financial fourth quarter of 2022 Landos Biopharma Inc earnings per share soared by 450.95 % at $0.66 per share, opposite of $0.12 per share a year prior reporting season, In the preceding reporting season LABP realized $-0.37 per share.